Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered question first ministerially corrected answering member label previous answer version answering member constituency answering member printed answering member
tabling member	label

Search

100186

	registered interest
	date	21/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Patients: Safety
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, whether missed or inadequate hydrocortisone administration is included in the NHS list of Never Events.
	tabling member constituency	Oxford East
	tabling member printed	Mr Andrew Smith
	uin	211233
	answer	answer is ministerial correction date of answer 28/10/2014 answer text <p>Missed or inadequate hydrocortisone administration is not currently included in the list of ‘never events’.</p><p> </p><p> </p><p> </p><p>We can confirm that the current list of Never Events is under review and there is a consultation underway which opened online on the 6 October 2014 and closes on 31 October 2014.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 28/10/2014 15:28:25 question first ministerially corrected 28/10/2014 16:30:53 answering member 4020 label Biography information for George Freeman previous answer version 24770 answering member constituency Battersea answering member printed Jane Ellison answering member 3918
	tabling member	95 label Biography information for Mr Andrew Smith

171817

	registered interest
	date	02/01/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hepatitis: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what response he has made to the request by NHS England to defer implementation of the guidance on sofosbuvir for hepatitis C.
	tabling member constituency	Oxford East
	tabling member printed	Mr Andrew Smith
	uin	219601
	answer	answer is ministerial correction date of answer 09/01/2015 answer text <p>As an independent body, it is for the National Institute for Health and Care Excellence (NICE), in consultation with stakeholders, to consider NHS England’s request to defer implementation of its guidance on sofosbuvir (Sovaldi) for the treatment of chronic hepatitis C.</p><p> </p><p> </p><p> </p><p>NICE recently consulted on extending the funding period and we understand that NICE expects to publish the outcome of that consultation, along with its final draft guidance on sofosbuvir, later this month. The Department’s response to the consultation will be published alongside other stakeholders’ comments. We are confident that NICE will carefully consider all the comments it has received before taking a final decision.</p><p> </p><p> </p><p> </p><p>NICE currently expects to publish its final guidance on sofosbuvir in February 2015, although this is subject to any appeals being received.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 219602 question first answered 09/01/2015 14:33:04 answering member 4020 label Biography information for George Freeman
	tabling member	95 label Biography information for Mr Andrew Smith

171818

	registered interest
	date	02/01/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hepatitis: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, when NICE guidance on the use of sofosbuvir for treating hepatitis C will be published.
	tabling member constituency	Oxford East
	tabling member printed	Mr Andrew Smith
	uin	219602
	answer	answer is ministerial correction date of answer 09/01/2015 answer text <p>As an independent body, it is for the National Institute for Health and Care Excellence (NICE), in consultation with stakeholders, to consider NHS England’s request to defer implementation of its guidance on sofosbuvir (Sovaldi) for the treatment of chronic hepatitis C.</p><p> </p><p> </p><p> </p><p>NICE recently consulted on extending the funding period and we understand that NICE expects to publish the outcome of that consultation, along with its final draft guidance on sofosbuvir, later this month. The Department’s response to the consultation will be published alongside other stakeholders’ comments. We are confident that NICE will carefully consider all the comments it has received before taking a final decision.</p><p> </p><p> </p><p> </p><p>NICE currently expects to publish its final guidance on sofosbuvir in February 2015, although this is subject to any appeals being received.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 219601 question first answered 09/01/2015 14:33:04 answering member 4020 label Biography information for George Freeman
	tabling member	95 label Biography information for Mr Andrew Smith

178985

	registered interest
	date	10/02/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hepatitis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to his Department's report, Hepatitis C in the UK, published in July 2014, what steps he is taking to approve for use new treatments for people with hepatitis C-related liver damage.
	tabling member constituency	Oxford East
	tabling member printed	Mr Andrew Smith
	uin	223984
	answer	answer is ministerial correction date of answer 23/02/2015 answer text <p>The Government is committed to ensuring that patients have access to clinically and cost effective treatments, including those for hepatitis C.</p><p> </p><p> </p><p> </p><p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing advice to the National Health Service on the clinical and cost-effectiveness of health technologies.</p><p> </p><p> </p><p> </p><p>NICE is currently appraising a number of new drugs for use in the treatment of hepatitis C under its technology appraisal process. These are shown in the following table.</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p>Drug/indication</p></td><td><p>Expected date of final guidance</p></td></tr><tr><td><p>sofosbuvir (Sovaldi) for treating chronic hepatitis C</p></td><td><p>February 2015</p></td></tr><tr><td><p>simeprevir (Olysio) for treating genotype 1 or 4 chronic hepatitis C</p></td><td><p>February 2015</p></td></tr><tr><td><p>ledipasvir-sofosbuvir (Harvoni) for treating chronic hepatitis C</p></td><td><p>June 2015</p></td></tr><tr><td><p>daclatasvir (Daklinza) for treating chronic hepatitis C</p></td><td><p>August 2015</p></td></tr><tr><td><p>ombitasvir/paritaprevir/ritonavir (Viekirax) with or without dasabuvir (Exviera) for treating chronic hepatitis C</p></td><td><p>September 2015</p></td></tr></tbody></table><p> </p><p><strong> </strong></p><p> </p><p>More generally, we have launched an Innovative Medicines and Medical Technology Review of the pathways for the development, assessment, and adoption of innovative medicines and medical technology. This review will consider how to speed up access for NHS patients to cost-effective new diagnostics, medicines and devices.</p><p> </p><p> </p><p> </p><p>The review will examine the pathway from ‘first in human’ trials, through licensing and health technology appraisal, to commissioning and clinical practice. It will set out both short and long-term options for action by Government and relevant bodies, including NICE, the Medicines and Healthcare products Regulatory Agency and NHS England, and mark a major contribution to the policy debate.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 23/02/2015 16:20:22 answering member 4020 label Biography information for George Freeman
	tabling member	95 label Biography information for Mr Andrew Smith

225476

	registered interest
	date	05/03/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hepatitis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, which medicines his Department plans to include in the fast track interim policy for hepatitis C medicines.
	tabling member constituency	Oxford East
	tabling member printed	Mr Andrew Smith
	uin	226494
	answer	answer is ministerial correction date of answer 12/03/2015 answer text <p>NHS England has advised that it is considering extending the current interim commissioning policy for Sofosbuvir plus ledipasvir (Harvoni) and another direct acting antiviral combination therapy for selected patients with cirrhosis associated with hepatitis C. The Department is not involved in this decision.</p><p> </p><p> </p><p> </p><p>NHS England has completed the evidence review and finalised its draft proposals. In doing so, it has engaged with clinical and patient stakeholders from the national lead Clinical Reference Group. NHS England has advised that the aim is that interim commissioning policies will be in place by the first half of 2015.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 226492 226493 question first answered 12/03/2015 14:26:47 answering member 4020 label Biography information for George Freeman
	tabling member	95 label Biography information for Mr Andrew Smith

225477

	registered interest
	date	05/03/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hepatitis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, who his Department and NHS England have consulted on the implementation of a fast track interim policy for hepatitis C patients from April 2015.
	tabling member constituency	Oxford East
	tabling member printed	Mr Andrew Smith
	uin	226492
	answer	answer is ministerial correction date of answer 12/03/2015 answer text <p>NHS England has advised that it is considering extending the current interim commissioning policy for Sofosbuvir plus ledipasvir (Harvoni) and another direct acting antiviral combination therapy for selected patients with cirrhosis associated with hepatitis C. The Department is not involved in this decision.</p><p> </p><p> </p><p> </p><p>NHS England has completed the evidence review and finalised its draft proposals. In doing so, it has engaged with clinical and patient stakeholders from the national lead Clinical Reference Group. NHS England has advised that the aim is that interim commissioning policies will be in place by the first half of 2015.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 226493 226494 question first answered 12/03/2015 14:26:46 answering member 4020 label Biography information for George Freeman
	tabling member	95 label Biography information for Mr Andrew Smith

225478

	registered interest
	date	05/03/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hepatitis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what progress has been made on the delivery of a fast track interim policy for hepatitis C medicines for patients who need it from April 2015.
	tabling member constituency	Oxford East
	tabling member printed	Mr Andrew Smith
	uin	226493
	answer	answer is ministerial correction date of answer 12/03/2015 answer text <p>NHS England has advised that it is considering extending the current interim commissioning policy for Sofosbuvir plus ledipasvir (Harvoni) and another direct acting antiviral combination therapy for selected patients with cirrhosis associated with hepatitis C. The Department is not involved in this decision.</p><p> </p><p> </p><p> </p><p>NHS England has completed the evidence review and finalised its draft proposals. In doing so, it has engaged with clinical and patient stakeholders from the national lead Clinical Reference Group. NHS England has advised that the aim is that interim commissioning policies will be in place by the first half of 2015.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 226492 226494 question first answered 12/03/2015 14:26:47 answering member 4020 label Biography information for George Freeman
	tabling member	95 label Biography information for Mr Andrew Smith

228171

	registered interest
	date	18/03/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Inflammatory Bowel Disease
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what funding there has been from the public purse for research into treatment of (a) Crohn's disease and (b) ulcerative colitis in the last five years.
	tabling member constituency	Oxford East
	tabling member printed	Mr Andrew Smith
	uin	228177
	answer	answer is ministerial correction date of answer 25/03/2015 answer text <p>The following table shows expenditure on research relating to the treatment of Crohn’s disease and ulcerative colitis by the Medical Research Council, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p>£ million</p><p> </p><table><tbody><tr><td><p> </p></td><td><p>2009/10</p></td><td><p>2010/11</p></td><td><p>2011/12</p></td><td><p>2012/13</p></td><td><p>2013/14</p></td></tr><tr><td colspan="6"><p>Crohn’s disease</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>3.1</p></td><td><p>3.4</p></td><td><p>2.6</p></td><td><p>2.4</p></td><td><p>2.5</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.4</p></td><td><p>0.6</p></td><td><p>0.3</p></td><td><p>0.8</p></td></tr><tr><td colspan="6"><p>Ulcerative colitis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>1.2</p></td><td><p>1.0</p></td><td><p>0.9</p></td><td><p>0.7</p></td><td><p>0.6</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.6</p></td><td><p>0.7</p></td><td><p>0.9</p></td><td><p>0.8</p></td><td><p>1.0</p></td></tr><tr><td colspan="6"><p>Crohn’s disease and ulcerative colitis</p></td></tr><tr><td><p>Medical Research Council<sup>1</sup></p></td><td><p>3.6</p></td><td><p>4.0</p></td><td><p>3.3</p></td><td><p>2.9</p></td><td><p>2.7</p></td></tr></tbody></table><p> </p><p><em>Note:</em></p><p> </p><p><sup>1</sup> Research looking at both Crohn’s disease and ulcerative colitis within the same project.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on research relating to the treatment of Crohn’s disease and ulcerative colitis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 25/03/2015 12:50:09 answering member 4020 label Biography information for George Freeman
	tabling member	95 label Biography information for Mr Andrew Smith

523535

	registered interest
	date	07/06/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	NHS: Reorganisation
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what accountability mechanics are in place related to decisions in Sustainability and Transformation Plan footprints.
	tabling member constituency	Oxford East
	tabling member printed	Mr Andrew Smith
	uin	39795
	answer	answer is ministerial correction date of answer 14/06/2016 answer text <p>Each Sustainability and Transformation Plan (STP) footprint is convened by a senior leader who has agreed to chair and lead the meetings on behalf of their peers. Each footprint has agreed its own governance and representation, depending on local circumstances and to ensure that all relevant National Health Service bodies and partners are included. An STP footprint supports organisations to come together to agree how best to improve and sustain services and health for their local populations.</p><p> </p><p>The local, statutory architecture for health and care remains. The arm's length bodies Regional Directors will retain accountability for delivery in their regions. Existing accountabilities for Chief Executives of provider organisations and Accountable Officers of Clinical Commissioning Groups are unchanged.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 14/06/2016 10:30:36 answering member 4020 label Biography information for George Freeman
	tabling member	95 label Biography information for Mr Andrew Smith

523539

	registered interest
	date	07/06/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	NHS: Reorganisation
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what the legal status is of the changes to health and social care proposed in Sustainability and Transformation Plans.
	tabling member constituency	Oxford East
	tabling member printed	Mr Andrew Smith
	uin	39771
	answer	answer is ministerial correction date of answer 13/06/2016 answer text <p>The Sustainability and Transformation Plans (STP) has no legal basis. Any plans submitted will be proposals that will form the basis for discussion. Depending on the level of local and national agreement, they may form the basis for further plans and actions that will be subject to the same legal and best practice requirements that govern the National Health Service.</p><p> </p><p>The local, statutory architecture for health and care remains, as do the existing accountabilities for Chief Executives of provider organisations and Accountable Officers of clinical commissioning groups. Organisations are still accountable for their individual organisational plans, which should form part of the first year of their footprint’s STP.</p><p> </p><p>The June STP submissions will be work-in-progress, and as such we do not anticipate the requirement for formal approval from boards and/or consultation at this early stage. Plans have no status until they are agreed. When plans are ready, normal rules around engagement and public consultation will apply.</p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 39613 question first answered 13/06/2016 14:32:38 answering member 4020 label Biography information for George Freeman
	tabling member	95 label Biography information for Mr Andrew Smith